Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. - Wikidata - wikimedia - TriplyDB

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

http://www.wikidata.org/entity/Q35352149

about

Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization?Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors Presence of sorbin in human digestive tract and endocrine digestive tumours Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews.Nonsurgical Strategies in Patients With NET Liver Metastases: A Protocol of Four Systematic Reviews.Incidence and management of malignant digestive endocrine tumours in a well defined French population.Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression Extensive multiarterial resection attending total duodenopancreatectomy and adrenalectomy for MEN-1-associated neuroendocrine carcinomas.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review.Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.Surgical treatment of liver metastases in neuroendocrine neoplasms.Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.Comparative study of non-functional islet cell tumors and pancreatic solid and papillary neoplasms: biological behavior and immunohistochemistry.Serum pancreastatin: the next predictive neuroendocrine tumor marker.Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms.Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.

P2860

Q24647838-97F04EDA-3DB2-4F41-813C-E9190BFAD676 Q24685837-695DD933-8B61-4367-8994-01E64DC941F4 Q26768483-CF1516F6-0E10-495F-8205-8A180F70E3AC Q28078948-D788E5A3-4BC8-43D8-8F88-9CC23D52D43B Q28290833-12A618CF-2FA9-4C0E-8D6C-103853C2063E Q28343873-CD4AAB00-12B6-48A7-90B6-5C89CA8C48F8 Q30249051-5AFB56EA-24FD-49E0-9648-9DFD236A8577 Q34182397-B5454DFF-BC0F-475A-90B1-2D1361DBFB2B Q34248466-E0026972-37D9-47DC-976B-FDFCA3ED6E40 Q35034000-4AA6E892-AE58-44C6-8993-C43C8DBDDAEC Q35065094-85EA8617-BD1A-4E32-8FA6-BDD724E8C06C Q35074937-982B0FE7-7743-4F2E-BDAD-7C74463628C7 Q35115068-30780567-41CF-4C31-8D8B-1EDAF218B2F5 Q35596395-1CBE42BD-2763-4FBB-98F1-806FC491150F Q35755390-998B51F0-6E57-40D6-83FD-3DA4DE1EAA4D Q35760798-D681615B-2EBD-4195-9787-BFAE95EF7199 Q35769184-16F40CF3-6557-45F1-A81B-E9F602E19AB7 Q35843079-F02F8FD2-D431-4726-9254-8C6CF91D0ADC Q35922060-9F95B91F-5743-4743-9A6E-26776611513F Q36335402-5D1A259F-82C5-4009-8633-EF8D4A2E3292 Q36344419-54C8C596-F57E-4B8E-9848-0AF6CB6C5D31 Q36610343-9693B92D-065F-49F6-8F73-0BDDF8B1D460 Q36610557-084F20C1-BB11-4D9F-ABB2-709DAA45C003 Q36615803-185B37D5-E074-47B6-B7BC-C72E003C890D Q36638258-3B36EBEE-931B-4BAE-9345-0645F6973CE3 Q37056120-90CC5452-A508-4EB3-9E90-882B77C16E62 Q37077358-7BA25640-6963-444D-A972-083A8ECE2AC6 Q37125550-7AF4083E-959F-4EFB-A95E-7D253C5CA905 Q37175960-86B8DE3C-62F7-4C97-8080-90A07A63A3FE Q37847859-730A4549-430B-4C33-A250-071F98EB9A39 Q37947138-40B5EDFA-5E38-4024-ABED-46685CE0DDB3 Q37982721-E8D97775-ED74-4BD8-A47E-D2D5191A4ADC Q43921041-BC019A23-5546-4086-8EFE-CB4DB50995B0 Q44052073-85F89546-A9E4-40AE-89F7-933C9F651DD2 Q44969569-B059E848-9268-44E7-B109-BD2877CC6BDB Q46945283-151F6549-ED52-439D-A43F-458FD979FD82 Q47194441-5293C96F-9621-48FA-852E-89A40C6E986E Q47230355-85AA2E3A-8AF7-4B17-BFBC-64C43300BA22 Q47615275-3A4EB22A-70E4-420E-BA30-C95899547FB6 Q48120130-C66E1D88-DC84-4CE2-8602-7B06DC130152

P2860

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

http://www.wikidata.org/entity/Q35352149

description

1998 nî lūn-bûn

@nan

1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@ast

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@en

type

label

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@ast

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@en

prefLabel

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@ast

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@en

P1433

Q35352149-56BAEF74-3E8C-4335-9041-AF9B826E1D23

P1476

Q35352149-BF5E00C9-5E36-4388-B8E7-23EF1B88287D

P2093

Q35352149-0AAF5E4D-287A-47EA-BD10-D4FC75F5EF9D

Q35352149-49115872-EE53-4EDD-81F6-894BDFF08C2D

Q35352149-77B8BF21-30C3-49A7-9888-97E87E81712D

Q35352149-843E3F3D-D6C6-497A-A25A-FECE115734DA

Q35352149-8CFD4A95-1E5C-4278-B260-479075DDEFC5

Q35352149-A1E6B066-A511-4009-ACBF-F0AF0E97D237

Q35352149-B418AEDE-16ED-44D1-A73B-9894C9089E17

Q35352149-BCC86975-18BC-4DDA-86EC-FB2DFD6C1A7D

Q35352149-C20EE3A9-D247-4228-BFCF-F810F4530859

Q35352149-FE6E12D7-8EA6-45FA-A976-CA774365D0B9

P2860

Q35352149-011C3185-F593-44B7-96F9-725009F3200B

Q35352149-0E34ECD0-C2B4-4B2D-8312-BDB1E63A6E05

Q35352149-166438D2-75CB-445A-9C4C-250FDD9550D9

Q35352149-299F7190-5B02-44AE-9332-BBB627466FBD

Q35352149-2EB7BFEE-8A82-4ECB-9B46-79B5402EEEC9

Q35352149-33D707D8-94E4-41B1-B6B0-245874D9BDF9

Q35352149-3474907E-56CE-48DE-BB9A-4D1475B003D9

Q35352149-72F5E955-1E31-4F4E-A153-B54580EF1AC7

Q35352149-785E32AC-5110-40E2-A19E-339237D49AA9

Q35352149-B2A9DFE5-3D1D-4305-BDC5-079E5A57E924

P304

Q35352149-E3D55005-FA77-483F-B37F-B418CD503BF1

P31

Q35352149-01AD4F86-90D7-420E-8966-6B419E168E2D

P356

Q35352149-5C4CDD26-CE54-469B-9788-C08B91DFD85B

P407

Q35352149-B5E7FD76-7E3A-49C1-B68E-DC6E145C2AB9

P433

Q35352149-9AC1F69E-6306-404E-8754-2D932240F6E4

P478

Q35352149-373E20A0-8889-4668-934C-0068C241F0D8

P577

Q35352149-3688F6CB-0B10-481B-9246-B668304C46CF

P5875

Q35352149-9821F363-EDAB-479D-9DBC-1C84B1A3D883

P698

Q35352149-9A280512-7495-4A0A-887D-207D39B7A7AF

P932

Q35352149-280880CF-4E91-42D9-A7F4-0747EF8B6CFB

P356

P1433

P1476

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

@en

P2093

Belghiti J

http://www.w3.org/2001/XMLSchema#string

Bernades P

http://www.w3.org/2001/XMLSchema#string

Denys A

http://www.w3.org/2001/XMLSchema#string

Flejou JF

http://www.w3.org/2001/XMLSchema#string

Madeira I

http://www.w3.org/2001/XMLSchema#string

Ruszniewski P

http://www.w3.org/2001/XMLSchema#string

Sauvanet A

http://www.w3.org/2001/XMLSchema#string

Terris B

http://www.w3.org/2001/XMLSchema#string

Vilgrain V

http://www.w3.org/2001/XMLSchema#string

Voss M

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.

Nucleolar organizer regions and glycoprotein-hormone alpha-chain reaction as markers of malignancy in endocrine tumours of the pancreas.

Cytoreductive hepatic surgery for neuroendocrine tumors.

Diagnosis and treatment of Zollinger-Ellison syndrome.

Operative and chemotherapeutic management of malignant glucagon-producing tumors.

Tumors of the endocrine pancreas.

Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course.

Current approach to the management of tumoral process in patients with gastrinoma.

Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin.

P304

422-427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.43.3.422

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

1998-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13423589

http://www.w3.org/2001/XMLSchema#string

P698

9863490

http://www.w3.org/2001/XMLSchema#string

P932

1727238

http://www.w3.org/2001/XMLSchema#string